Jonathan Melamed

Jonathan Melamed

Auto-generated profile, based on publicly available information

Jonathan Melamed

Department of Pathology, New York University Langone Medical Center, New York, NY

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Cell
Verified
Journal Article
Closed access
JAJuan C. Acosta
Juan C. Acosta
AOAna O'Loghlen
Ana O'Loghlen
ABAna Banito
Ana Banito
MGMaria V. Guijarro
Maria V. Guijarro
AAArnaud Augert
Arnaud Augert
JGJesús Gil
Jesús Gil

15 March 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZGZhiyong Guo
Zhiyong Guo
XYXi Yang
Xi Yang
FSFeng Sun
Feng Sun
RJRicheng Jiang
Richeng Jiang
DLDouglas E. Linn
Douglas E. Linn
YQYun Qiu
Yun Qiu
The androgen receptor (AR) plays a key role in progression to incurable androgen ablation–resistant prostate cancer (PCA). We have identified three novel AR splice variants lacking the ligand-binding domain (designated as AR3, AR4, and AR5) in hormone-insensitive PCA cells. AR3, one of the major splice variants expressed in human prostate tissues, is constitutively active, and its transcriptional activity is not regulated by androgens or antiandrogens. Immunohistochemistry analysis on tissue microarrays containing 429 human prostate tissue samples shows that AR3 is significantly up-regulated during PCA progression and AR3 expression level is correlated with the risk of tumor recurrence after radical prostatectomy. Overexpression of AR3 confers ablation-independent growth of PCA cells, whereas specific knockdown of AR3 expression (without altering AR level) in hormone-resistant PCA cells attenuates their growth under androgen-depleted conditions in both cell culture and xenograft models, suggesting an indispensable role of AR3 in ablation-independent growth of PCA cells. Furthermore, AR3 may play a distinct, yet essential, role in ablation-independent growth through the regulation of a unique set of genes, including AKT1, which are not regulated by the prototype AR. Our data suggest that aberrant expression of AR splice variants may be a novel mechanism underlying ablation independence during PCA progression, and AR3 may serve as a prognostic marker to predict patient outcome in response to hormonal therapy. Given that these novel AR splice variants are not inhibited by currently available antiandrogen drugs, development of new drugs targeting these AR isoforms may potentially be effective for treatment of ablation-resistant PCA. [Cancer Res 2009;69(6):2305–13]

26 May 2020 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
GLGeert J.L.H. van Leenders
Geert J.L.H. van Leenders
TKTheodorus H. van der Kwast
Theodorus H. van der Kwast
DGDavid J. Grignon
David J. Grignon
AEAndrew J. Evans
Andrew J. Evans
GKGlen Kristiansen
Glen Kristiansen
KIKenneth A Iczkowski
Kenneth A Iczkowski
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging–targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.

1 October 2013 in European Urology
Verified
Journal Article
Closed access
CMCaroline M. Moore
Caroline M. Moore
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
SEScott Eggener
Scott Eggener
MEMark Emberton
Mark Emberton
JFJurgen J. Fütterer
Jurgen J. Fütterer
YWYuji Watanabe
Yuji Watanabe

1 August 2014 in European Urology
Verified
Journal Article
Closed access
JWJames S. Wysock
James S. Wysock
ARAndrew B. Rosenkrantz
Andrew B. Rosenkrantz
WHWilliam C. Huang
William C. Huang
MSMichael D. Stifelman
Michael D. Stifelman
HLHerbert Lepor
Herbert Lepor
STSamir S. Taneja
Samir S. Taneja

1 October 2006 in Cancer Cell
Verified
Journal Article
Closed access
ZGZhiyong Guo
Zhiyong Guo
BDBojie Dai
Bojie Dai
TJTianyun Jiang
Tianyun Jiang
KXKexin Xu
Kexin Xu
YXYingqiu Xie
Yingqiu Xie
YQYun Qiu
Yun Qiu